VANI

Vivani Medical, Inc. (VANI) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Vivani Medical, Inc. is a clinical-stage biopharmaceutical company developing miniature, ultra long-acting subdermal drug implants using its proprietary NanoPortal technology. The company operates two segments: the Biopharm Division (primary focus) and the Neurostimulation Division (Cortigent, Inc., a subsidiary being spun off). Vivani has no product revenue to date and relies on equity financing to fund operations.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company reported no revenue for any period presented.

Material Changes vs. Prior Period

• Increased Burn Rate: Net loss for the six months ended June 30, 2025, increased by approximately 18% compared to the same period in 2024, driven by higher Research and Development (R&D) expenses ($9.0M vs. $7.2M) and General and Administrative (G&A) expenses ($5.0M vs. $4.7M).
• Liquidity Decline: Cash, cash equivalents, and restricted cash decreased by $11.6 million from $19.7 million at year-end 2024 to $8.1 million at June 30, 2025. Working capital dropped significantly from $14.5 million to $2.0 million.
• Segment Performance: The Biopharm Division accounted for the majority of expenses ($12.7M operating expenses YTD 2025), while the Neurostimulation Division incurred $1.3M.

Guidance, Outlook, and Risks

• Clinical Milestones: The LIBERATE-1 first-in-human clinical trial for NPM-115 (exenatide implant) achieved full enrollment in four weeks. Top-line results are expected in mid-2025. Based on positive safety data, the company plans to prioritize the advancement of NPM-139 (semaglutide implant), with clinical development expected to begin in 2026.
• Capital Resources: Management estimates current cash will fund operations for at least the next twelve months. However, the company expects to continue incurring losses and will require additional capital. Three equity purchase agreements entered in March, May, and August 2025 are expected to bring $21.25 million in committed capital between September 2025 and July 2026.
• Strategic Spin-off: Vivani is proceeding with the spin-off of its Cortigent neuromodulation business. A Form 10 registration statement was filed in May 2025, with the transaction planned for completion in Q3 or Q4 2025.
• Legal Contingencies:
  • Pixium Vision: A pending appeal in the Paris Court of Appeal regarding a terminated MOU. The company's appeal was struck out in October 2024 for failure to enforce a prior judgment; Vivani must request reinstatement within two years. A litigation accrual of $1.675 million remains on the balance sheet.
  • Oppenheimer & Co.: A breach of contract claim seeking $1.625 million is in discovery after partial dismissal of other claims.
• Regulatory/Tax: The "One Big Beautiful Bill Act" signed in July 2025 eliminates the requirement to capitalize R&D expenditures, making them fully deductible in the period incurred.

Investor Verification Checklist

• Cash Runway: Verify the timing and certainty of the $21.25 million in committed capital from recent equity agreements to confirm the "12-month" liquidity estimate.
• LIBERATE-1 Data: Monitor the release of mid-2025 top-line data from the NPM-115 trial, which is critical for the advancement of the NPM-139 program.
• Cortigent Spin-off: Track the progress of the Form 10 registration and the finalization of the spin-off to understand the future capital structure and asset separation.
• Legal Exposure: Assess the status of the Pixium appeal reinstatement and the potential financial impact of the Oppenheimer litigation.
• Expense Trajectory: Review future R&D spend projections given the strategic shift to prioritize NPM-139 and the potential for increased clinical trial costs.